Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07868926 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of VX-407 following a single oral dose.
Trial Details
NCT Number NCT07868926
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov